NASDAQ:SNSE - Sensei Biotherapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.00
  • Forecasted Upside: 73.56 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.49
▲ +0.29 (4.03%)

This chart shows the closing price for SNSE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sensei Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SNSE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SNSE

Analyst Price Target is $13.00
▲ +73.56% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Sensei Biotherapeutics in the last 3 months. The average price target is $13.00, with a high forecast of $14.00 and a low forecast of $12.00. The average price target represents a 73.56% upside from the last price of $7.49.

This chart shows the closing price for SNSE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Sensei Biotherapeutics.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/6/2021Piper SandlerLower Price TargetOverweight$25.00 ➝ $12.00Low
7/5/2021AlphaValueDowngradeBuyLow
7/1/2021Berenberg BankDowngradeBuy ➝ Hold$12.00High
6/29/2021CitigroupLower Price TargetBuy$30.00 ➝ $14.00High
6/29/2021OppenheimerDowngradeOutperform ➝ Market Perform$30.00 ➝ $14.00High
3/1/2021OppenheimerInitiated CoverageOutperform$36.00Low
3/1/2021CitigroupInitiated CoverageBuy$30.00Low
3/1/2021Berenberg BankInitiated CoverageBuy$27.00Low
3/1/2021Piper SandlerInitiated CoverageOverweight$25.00Low
(Data available from 7/23/2016 forward)
Sensei Biotherapeutics logo
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $7.49
Low: $7.14
High: $7.59

50 Day Range

MA: $10.42
Low: $6.97
High: $13.68

52 Week Range

Now: $7.49
Low: $6.80
High: $26.50

Volume

53,994 shs

Average Volume

117,418 shs

Market Capitalization

$229.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sensei Biotherapeutics?

The following sell-side analysts have issued reports on Sensei Biotherapeutics in the last twelve months: AlphaValue, Berenberg Bank, Citigroup Inc., Oppenheimer Holdings Inc., Piper Sandler, and Zacks Investment Research.
View the latest analyst ratings for SNSE.

What is the current price target for Sensei Biotherapeutics?

4 Wall Street analysts have set twelve-month price targets for Sensei Biotherapeutics in the last year. Their average twelve-month price target is $13.00, suggesting a possible upside of 73.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting SNSE will reach $14.00 in the next twelve months. Berenberg Bank has the lowest price target set, forecasting a price of $12.00 for Sensei Biotherapeutics in the next year.
View the latest price targets for SNSE.

What is the current consensus analyst rating for Sensei Biotherapeutics?

Sensei Biotherapeutics currently has 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SNSE will outperform the market and that investors should add to their positions of Sensei Biotherapeutics.
View the latest ratings for SNSE.

What other companies compete with Sensei Biotherapeutics?

How do I contact Sensei Biotherapeutics' investor relations team?

Sensei Biotherapeutics' physical mailing address is 1405 RESEARCH BLVD SUITE 125, ROCKVILLE MD, 20850. The company's listed phone number is 240 243 8000 and its investor relations email address is [email protected] The official website for Sensei Biotherapeutics is www.senseibio.com.